Alexandre Chan: Updates on repurposing riluzole as a treatment for cancer-related cognitive impairment
Alexandre Chan, President-Elect of MASCC, shared a post on LinkedIn about a recent paper by him and colleagues published in Acta Neuropathologica Communications:
“Some updates regarding our quest to repurpose riluzole as treatment for cancer-related cognitive impairment.
In our latest manuscript published in Acta Neuropathologica Communications:
- Riluzole is associated with, reduced neuroinflammation, increased neuronal BDNF and improved cognition in radiotherapy (RT)-exposed mice
- In our spatial transcriptomics profiling, a significant increase in the bdnf gene expression in hippocampal excitatory neurons in the riluzole-treated was observed.
On a separate note, our Phase 2 study on riluzole for chemobrain just opened for patient recruitment! With this new data it’s time to design a separate trial to evaluate riluzole’s role in RT-induced cognitive impairment.
Great collaboration with the Acharya and Xu’s labs!”
Authors: Sanad El‑Khatib, Arya Vagadia, Anh Le, Janet Baulch, Ding Quan Ng, Mingyu Du, Kevin Johnston, Zhiqun Tan, Xiangmin Xu, Alexandre Chan, Munjal Acharya.
Alexandre Chan, PharmD, MPH, FCCP, FISOPP, BCPS, BCOP, APh, is the President-Elect of the Multinational Association of Supportive Care in Cancer (MASCC) and Associate Editor-in-Chief of Supportive Care in Cancer.
He is the Founding Chair and Professor of Clinical Pharmacy Practice at the UCI School of Pharmacy and Pharmaceutical Sciences and serves as Associate Editor of the Journal of Oncology Pharmacy Practice. Previously, he was President of the International Society of Oncology Pharmacy Practitioners (ISOPP).
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023